Heart failure is one of the most common causes of hospital emergency admissions (5%), re-admissions and bed day occupancy, and these rates are predicted to increase in the future. Of all heart failure admissions, 90% are due to fluid overload. Currently, loop diuretics are the ‘hallmark’ treatment, however some patients become resistant to diuretic therapy over time and diuretics have a high rate of adverse effects. Considering the large number of patients, increased morbidity, mortality rates and resource use, current management strategies are not optimal: new therapies are required and should be evaluated thoroughly. Aquapheresis (AQ) is a non-pharmacological procedure that removes excess water and sodium from the blood via a filter using a simplified ultrafiltration (UF) device. This article discusses AQ as a treatment option. AQ is a relatively new therapy in the UK and has some advantages over conventional therapy. In particular, patients can be treated with AQ in a cardiology setting, this may allow rapid removal of excess fluid and earlier discharge. Close consultant supervision and input is required with dedicated nursing staff managing the patient. A formal UK health economic analysis is required. AQ provides a feasible, additional treatment option for patients with heart failure in the UK, which are significantly limited at present.